miRNAs have emerged as major players in the pathogenesis and progression of NAFLD, with altered hepatic expression of miR-122, -192, and -128-3p disrupting several facets of hepatic lipid metabolism, insulin sensitivity, and cholesterol-lipoprotein trafficking [29,35,47]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.